Diagnostic and clinical utility of antibodies against the nuclear body promyelocytic leukaemia and Sp100 antigens in patients with primary biliary cirrhosis

The lack of an immunoassay that detects antibodies to promyelocytic leukaemia (PML) protein, the primary biliary cirrhosis (PBC)-specific multiple nuclear dot (MND) antigen, has prompted us to develop a line immunoassay (LIA) for the simultaneous detection of PML and Sp100 MND-specific autoantibodie...

Full description

Saved in:
Bibliographic Details
Published in:Clinica chimica acta 2012-08, Vol.413 (15-16), p.1211-1216
Main Authors: Mytilinaiou, Maria G., Meyer, Wolfgang, Scheper, Thomas, Rigopoulou, Eirini I., Probst, Christian, Koutsoumpas, Andreas L., Abeles, Daniel, Burroughs, Andrew K., Komorowski, Lars, Vergani, Diego, Bogdanos, Dimitrios P.
Format: Article
Language:English
Subjects:
Adult
Amino Acid Sequence
Anti-nuclear antibody
Antibody Specificity
Antigens, Nuclear - analysis
Antigens, Nuclear - blood
Antigens, Nuclear - genetics
Antigens, Nuclear - immunology
Autoantibodies - analysis
Autoantibodies - blood
Autoantibodies - immunology
Autoantigens - analysis
Autoantigens - blood
Autoantigens - genetics
Autoantigens - immunology
Autoimmune hepatitis
Autoimmune liver disease
Autoimmunity
Case-Control Studies
Cholestasis
Escherichia coli - genetics
Follow-Up Studies
Humans
Immunoassay - methods
Leukemia, Promyelocytic, Acute - diagnosis
Leukemia, Promyelocytic, Acute - immunology
Liver Cirrhosis, Biliary - diagnosis
Liver Cirrhosis, Biliary - immunology
Middle Aged
Molecular Sequence Data
Nuclear dots
Time Factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The lack of an immunoassay that detects antibodies to promyelocytic leukaemia (PML) protein, the primary biliary cirrhosis (PBC)-specific multiple nuclear dot (MND) antigen, has prompted us to develop a line immunoassay (LIA) for the simultaneous detection of PML and Sp100 MND-specific autoantibodies. PML and Sp100 were expressed in Escherichia coli, and analysed by SDS-PAGE and immunoblotting using a monoclonal antibody and MALDI-ToF fingerprinting. A quantitative PML and Sp100 LIA were developed and testing was performed in 150 anti-mitochondrial antibody (AMA) positive, 20 AMA-PBCs and 130 controls. Thirty-five (23%) of 150 AMA+ PBCs (18 anti-MND+) were anti-PML+ (12%) or anti-Sp100+ (20%), 10 being anti-PML+/Sp100+, 5 single anti-PML+ and 20 single anti-Sp100+. Six (30%, 5 anti-MND+) AMA-PBCs were anti-PML+ or Sp100+. Only 2 (1.7%) pathological controls were anti-PML+ and/or anti-Sp100+. Levels of anti-PML correlated with those of anti-Sp100 (R=0.64, p
ISSN:0009-8981
1873-3492
DOI:10.1016/j.cca.2012.03.020